Cipher Pharmaceuticals Inc. (CPH.TO)
CAD 14.56
(3.41%)
CAD 14.56
(3.41%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 5.56 Million USD | 25.33% |
| 2022 | 5.63 Million USD | -12.67% |
| 2021 | 6.45 Million USD | 1.0% |
| 2020 | 6.38 Million USD | -20.6% |
| 2019 | 8.04 Million USD | -47.44% |
| 2018 | 15.3 Million USD | 16.14% |
| 2017 | 13.17 Million USD | -66.01% |
| 2016 | 38.75 Million USD | 21.3% |
| 2015 | 31.95 Million USD | 165.03% |
| 2014 | 12.05 Million USD | 47.36% |
| 2013 | 8.18 Million USD | 34.1% |
| 2012 | 6.1 Million USD | 4.35% |
| 2011 | 5.84 Million USD | 8.38% |
| 2010 | 5.39 Million USD | -6.14% |
| 2009 | 5.74 Million USD | 29.41% |
| 2008 | 4.44 Million USD | -42.32% |
| 2007 | 7.69 Million USD | -30.81% |
| 2006 | 11.12 Million USD | -25.05% |
| 2005 | 14.84 Million USD | -52.76% |
| 2004 | 31.42 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 1.75 Million USD | 10.09% |
| 2024 Q2 | 1.6 Million USD | -8.42% |
| 2023 Q2 | 1.93 Million USD | 23.61% |
| 2023 Q4 | 1.59 Million USD | -18.94% |
| 2023 Q1 | 1.56 Million USD | 11.56% |
| 2023 FY | 7.06 Million USD | 25.33% |
| 2023 Q3 | 1.96 Million USD | 1.92% |
| 2022 Q2 | 1.11 Million USD | -19.81% |
| 2022 Q4 | 1.4 Million USD | -18.64% |
| 2022 FY | 5.63 Million USD | -12.67% |
| 2022 Q1 | 1.39 Million USD | 35.9% |
| 2022 Q3 | 1.72 Million USD | 54.16% |
| 2021 Q4 | 1.02 Million USD | -39.81% |
| 2021 Q1 | 2.45 Million USD | 29.0% |
| 2021 Q2 | 1.26 Million USD | -48.23% |
| 2021 Q3 | 1.7 Million USD | 34.2% |
| 2021 FY | 6.45 Million USD | 1.0% |
| 2020 FY | 6.38 Million USD | -20.6% |
| 2020 Q1 | 1.46 Million USD | 5.4% |
| 2020 Q2 | 1.33 Million USD | -9.22% |
| 2020 Q3 | 1.69 Million USD | 27.07% |
| 2020 Q4 | 1.9 Million USD | 12.43% |
| 2019 Q2 | 2.12 Million USD | -29.09% |
| 2019 Q4 | 1.39 Million USD | -9.09% |
| 2019 Q3 | 1.52 Million USD | -28.08% |
| 2019 FY | 8.04 Million USD | -47.44% |
| 2019 Q1 | 2.99 Million USD | -41.33% |
| 2018 Q2 | 3.54 Million USD | 2.66% |
| 2018 FY | 15.3 Million USD | 16.14% |
| 2018 Q4 | 5.11 Million USD | 59.99% |
| 2018 Q3 | 3.19 Million USD | -9.9% |
| 2018 Q1 | 3.45 Million USD | -3.03% |
| 2017 Q3 | 3.44 Million USD | 10.28% |
| 2017 Q1 | 3.05 Million USD | 139.09% |
| 2017 FY | 13.17 Million USD | -66.01% |
| 2017 Q4 | 3.56 Million USD | 3.43% |
| 2017 Q2 | 3.12 Million USD | 2.36% |
| 2016 Q3 | 26.91 Million USD | 159.45% |
| 2016 FY | 38.75 Million USD | 21.3% |
| 2016 Q2 | 10.37 Million USD | 11.78% |
| 2016 Q1 | 9.27 Million USD | -13.84% |
| 2016 Q4 | -7.8 Million USD | -128.99% |
| 2015 Q3 | 9.78 Million USD | 28.45% |
| 2015 FY | 31.95 Million USD | 165.03% |
| 2015 Q4 | 10.76 Million USD | 10.01% |
| 2015 Q2 | 7.62 Million USD | 106.36% |
| 2015 Q1 | 3.69 Million USD | 25.7% |
| 2014 Q4 | 2.93 Million USD | 27.3% |
| 2014 FY | 12.05 Million USD | 47.36% |
| 2014 Q1 | 2.58 Million USD | 52.44% |
| 2014 Q2 | 2.59 Million USD | 0.56% |
| 2014 Q3 | 2.3 Million USD | -11.17% |
| 2013 Q4 | 1.69 Million USD | -24.8% |
| 2013 Q2 | 2.39 Million USD | 31.88% |
| 2013 Q1 | 1.81 Million USD | 25.17% |
| 2013 FY | 8.18 Million USD | 34.1% |
| 2013 Q3 | 2.25 Million USD | -5.86% |
| 2012 Q4 | 1.45 Million USD | 1.17% |
| 2012 FY | 6.1 Million USD | 4.35% |
| 2012 Q1 | 1.71 Million USD | 7.35% |
| 2012 Q2 | 1.42 Million USD | -16.69% |
| 2012 Q3 | 1.43 Million USD | 0.28% |
| 2011 Q2 | 1.29 Million USD | -29.31% |
| 2011 FY | 5.84 Million USD | 8.38% |
| 2011 Q1 | 1.83 Million USD | 47.92% |
| 2011 Q4 | 1.59 Million USD | 21.16% |
| 2011 Q3 | 1.31 Million USD | 1.73% |
| 2010 FY | 5.39 Million USD | -6.14% |
| 2010 Q3 | 1.32 Million USD | -6.36% |
| 2010 Q2 | 1.41 Million USD | 0.14% |
| 2010 Q1 | 1.4 Million USD | -6.96% |
| 2010 Q4 | 1.24 Million USD | -6.11% |
| 2009 Q4 | 1.51 Million USD | 0.45% |
| 2009 FY | 5.74 Million USD | 29.41% |
| 2009 Q1 | 1.12 Million USD | 273.91% |
| 2009 Q2 | 1.28 Million USD | 13.65% |
| 2009 Q3 | 1.5 Million USD | 17.51% |
| 2008 Q4 | 301.81 Thousand USD | -59.76% |
| 2008 FY | 4.44 Million USD | -42.32% |
| 2008 Q3 | 750.04 Thousand USD | -65.19% |
| 2008 Q2 | 2.15 Million USD | 58.98% |
| 2008 Q1 | 1.35 Million USD | -32.29% |
| 2007 Q4 | 2 Million USD | 35.56% |
| 2007 Q3 | 1.47 Million USD | -31.89% |
| 2007 FY | 7.69 Million USD | -30.81% |
| 2007 Q1 | 1.63 Million USD | 10.42% |
| 2007 Q2 | 2.16 Million USD | 32.9% |
| 2006 Q4 | 1.47 Million USD | -27.39% |
| 2006 Q2 | 4.62 Million USD | 61.13% |
| 2006 Q3 | 2.03 Million USD | -56.03% |
| 2006 FY | 11.12 Million USD | -25.05% |
| 2006 Q1 | 2.87 Million USD | -34.95% |
| 2005 Q2 | 4.43 Million USD | 104.77% |
| 2005 Q3 | 3.5 Million USD | -20.95% |
| 2005 Q4 | 4.41 Million USD | 25.92% |
| 2005 FY | 14.84 Million USD | -52.76% |
| 2005 Q1 | 2.16 Million USD | 0.0% |
| 2004 Q2 | 8.31 Million USD | 119.93% |
| 2004 Q1 | 3.78 Million USD | 0.0% |
| 2004 Q3 | -9.3 Million USD | -211.9% |
| 2004 FY | 31.42 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Aurora Cannabis Inc. | 158.53 Million CAD | 96.49% |
| Avicanna Inc. | 14.59 Million CAD | 61.869% |
| Avant Brands Inc. | 5.65 Million CAD | 1.679% |
| Cardiol Therapeutics Inc. | 29.53 Million CAD | 81.163% |
| Crescita Therapeutics Inc. | 12.32 Million CAD | 54.838% |
| Knight Therapeutics Inc. | 155.54 Million CAD | 96.423% |
| MediPharm Labs Corp. | 23.08 Million CAD | 75.896% |
| OrganiGram Holdings Inc. | 277.81 Million CAD | 97.997% |
| Canopy Growth Corporation | 308.61 Million CAD | 98.197% |
| Willow Biosciences Inc. | 7.55 Million CAD | 26.344% |
| Auxly Cannabis Group Inc. | 40.28 Million CAD | 86.187% |